The prevalence of severe bacterial infections (SBIs), defined as urinary tract infection (UTI), bacterial gastroenteritis, and more invasive bacterial infections (IBIs), such as bacteremia and meningitis, varies from 5% to 15% in infants younger than 3 months, and diagnostically reliable symptoms or clinical signs are few.
1-5 Therefore, it can be difficult to distinguish young infants with SBIs from those with viral infection. As a result, a complete sepsis evaluation, empirical antibiotic therapy, and hospital admission are recommended for febrile infants up to 1 month of age and are common for those 1 to 2 months of age.
1,2,4,6 Clinicobiological scores to identify patients at low risk of SBI have been developed to allow optimal treatment.
1,6-8 These scores are less accurate in infants younger than 1 month,
9-11 difficult to use in practice,
12 and variably applied by physicians.
3,12-15 Their cost and the associated iatrogenic morbidity have not been extensively evaluated. Management of such cases could be improved by new tools, and candidates include diagnostic tests for viral infection
9,16 and procalcitonin (PCT) assays with earlier detection than usual biomarkers. The value of the PCT assay has been evaluated for the detection of SBI in infants
17-22 and more specifically of IBI,
23-25 and the findings are favorable. However, to our knowledge, few studies
26-29 have assessed the performance of PCT assays for infants up to 3 months of age. The objective of this prospective study was to assess the diagnostic accuracy of PCT assays and to compare it with other, routinely used biomarkers for detecting SBI and IBI in febrile infants aged 7 to 91 days and for subgroups of infants according to their age (7-30 days or >30 days) and the duration of fever (≤6 hours).